IDEXX Laboratories (IDXX) to Release Quarterly Earnings on Wednesday

IDEXX Laboratories (NASDAQ:IDXXGet Rating) is scheduled to be releasing its earnings data before the market opens on Wednesday, May 4th. Analysts expect IDEXX Laboratories to post earnings of $2.26 per share for the quarter. IDEXX Laboratories has set its FY22 guidance at $9.27-$9.59 EPS.Persons interested in registering for the company’s conference call can do so using this link.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last released its earnings results on Wednesday, February 2nd. The company reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.22. The business had revenue of $801.00 million for the quarter, compared to analyst estimates of $781.83 million. IDEXX Laboratories had a return on equity of 102.84% and a net margin of 23.17%. IDEXX Laboratories’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.01 earnings per share. On average, analysts expect IDEXX Laboratories to post $9 EPS for the current fiscal year and $11 EPS for the next fiscal year.

IDXX stock opened at $455.56 on Wednesday. The company has a market cap of $38.38 billion, a price-to-earnings ratio of 52.91, a P/E/G ratio of 4.00 and a beta of 1.00. IDEXX Laboratories has a twelve month low of $455.34 and a twelve month high of $706.95. The business has a 50 day moving average price of $518.63 and a two-hundred day moving average price of $567.11. The company has a quick ratio of 0.90, a current ratio of 1.25 and a debt-to-equity ratio of 1.12.

In other news, Director Jonathan W. Ayers sold 250 shares of the stock in a transaction dated Tuesday, February 15th. The shares were sold at an average price of $509.70, for a total value of $127,425.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.06% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $28,000. Salem Investment Counselors Inc. acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth $39,000. Monolith Advisors bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $66,000. KB Financial Partners LLC acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $72,000. Finally, Integrated Wealth Concepts LLC bought a new position in IDEXX Laboratories during the fourth quarter worth about $212,000. Institutional investors own 83.80% of the company’s stock.

Several equities analysts recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Wednesday, February 2nd. began coverage on shares of IDEXX Laboratories in a research report on Thursday, March 31st. They issued a “buy” rating for the company. Finally, Atlantic Securities initiated coverage on shares of IDEXX Laboratories in a report on Tuesday, February 8th. They issued an “overweight” rating and a $650.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from, the stock has an average rating of “Buy” and a consensus target price of $702.40.

IDEXX Laboratories Company Profile (Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Featured Stories

Earnings History for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with's FREE daily email newsletter.